Adelle P McFarland
Overview
Explore the profile of Adelle P McFarland including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
398
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stamm C, McFarland A, Locke M, Tabakh H, Tang Q, Thomason M, et al.
mBio
. 2024 Jun;
15(8):e0133224.
PMID: 38940553
Importance: is the gram-positive bacterium responsible for the food-borne disease listeriosis. Although infections with are limiting in healthy hosts, vulnerable populations, including pregnant and elderly people, can experience high rates...
2.
Camargo A, McFarland A, Woodward J, Nero L
Int J Food Microbiol
. 2022 Sep;
382:109906.
PMID: 36108483
Listeriosis is a foodborne disease caused by the Gram-positive bacterium Listeria monocytogenes, a pathogen that modulates its intracellular survival via vacuolar escape and cytosolic replication. In the present study, we...
3.
Tang Q, Precit M, Thomason M, Blanc S, Ahmed-Qadri F, McFarland A, et al.
Cell Host Microbe
. 2022 Apr;
30(7):961-974.e6.
PMID: 35439435
Antimicrobials can impact bacterial physiology and host immunity with negative treatment outcomes. Extensive exposure to antifolate antibiotics promotes thymidine-dependent Staphylococcus aureus small colony variants (TD-SCVs), commonly associated with worse clinical...
4.
Tabakh H, McFarland A, Thomason M, Pollock A, Glover R, Zaver S, et al.
Elife
. 2021 May;
10.
PMID: 33955352
Pathogens encounter numerous antimicrobial responses during infection, including the reactive oxygen species (ROS) burst. ROS-mediated oxidation of host membrane poly-unsaturated fatty acids (PUFAs) generates the toxic alpha-beta carbonyl 4-hydroxy-2-nonenal (4-HNE)....
5.
McFarland A, Yalin A, Wang S, Cortez V, Landsberger T, Sudan R, et al.
Immunity
. 2021 May;
54(6):1320-1337.e4.
PMID: 33945787
Natural killer (NK) cells and type 1 innate lymphoid cells (ILC1s) are heterogenous innate lymphocytes broadly defined in mice as LinNK1.1NKp46 cells that express the transcription factor T-BET and produce...
6.
McFarland A, Colonna M
Curr Opin Immunol
. 2019 Dec;
62:9-14.
PMID: 31825814
Tissue-resident lymphocytes that lack expression of rearranged antigen receptors and are lineage negative for classical T and B cell markers are collectively known as innate lymphoid cells (ILCs). The ILC...
7.
Camargo A, Moura A, Avillan J, Herman N, McFarland A, Sreevatsan S, et al.
Environ Microbiol
. 2019 Jun;
21(12):4478-4487.
PMID: 31251828
Advances in whole-genome sequencing (WGS) technologies have documented genetic diversity and epidemiology of the major foodborne pathogen Listeria monocytogenes (Lm) in Europe and North America, but data concerning South America...
8.
McFarland A, Burke T, Carletti A, Glover R, Tabakh H, Welch M, et al.
mBio
. 2018 May;
9(3).
PMID: 29764944
The oxidoreductase RECON is a high-affinity cytosolic sensor of bacterium-derived cyclic dinucleotides (CDNs). CDN binding inhibits RECON's enzymatic activity and subsequently promotes inflammation. In this study, we sought to characterize...
9.
McFarland A, Luo S, Ahmed-Qadri F, Zuck M, Thayer E, Goo Y, et al.
Immunity
. 2017 Mar;
46(3):433-445.
PMID: 28329705
Bacterial and host cyclic dinucleotides (cdNs) mediate cytosolic immune responses through the STING signaling pathway, although evidence suggests that alternative pathways exist. We used cdN-conjugated beads to biochemically isolate host...
10.
Jarret A, McFarland A, Horner S, Kell A, Schwerk J, Hong M, et al.
Nat Med
. 2016 Nov;
22(12):1475-1481.
PMID: 27841874
Hepatitis C virus (HCV) infects 200 million people globally, and 60-80% of cases persist as a chronic infection that will progress to cirrhosis and liver cancer in 2-10% of patients....